Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.0B
60M shares
52-week range
$22.24 – $46.00
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
www.agios.comNo one on the platform currently holds AGIO.
No tracked institution reports a position in AGIO as of their last filing.
No one on the platform has traded AGIO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 48.0% | |||||
| Profit Margin % | -764.0% | |||||
| Free Cash Flow Margin % | -698.3% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $183M | +295.7% | $-5.68 | $-6.77–$-5.08 | — | 8 |
| 2027 | $352M | +92.6% | $-3.69 | $-5.47–$-2.33 | — | 9 |
| 2028 | $519M | +47.6% | $-1.72 | $-3.53–$0.49 | — | 8 |
| 2029 | $653M | +25.9% | $-0.39 | $-0.51–$-0.26 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $-1.65 | $-1.69 | -2.4% |
| 2026-04-29 | $-1.81 | $-1.69 | +6.6% |
| 2026-02-12 | $-1.97 | $-1.85 | +6.1% |
| 2025-10-30 | $-1.93 | $-1.78 | +7.8% |
| 2025-07-31 | $-1.74 | $-1.93 | -10.9% |
| 2025-05-01 | $-1.80 | $-1.55 | +13.9% |
| 2025-02-13 | $-1.69 | $-1.74 | -3.0% |
| 2024-10-31 | $15.22 |
| $16.22 |
| +6.6% |
| $2.2B |
| — |
| GLPGGalapagos N.V. | $27.98 | +1.71% | $1.8B | — |
| IBRXImmunityBio, Inc. | $7.72 | -4.22% | $8.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@stu4 $AGIO I don't dig that deep. Why do you need that stress?What is important here? For me the following info: 1. "The FDA accepted Agios's sNDA under Priority Review and assigned a November 1, 2026 PDUFA date under the accelerated-approval pathway" 2. Cash position and runway. As of June 30, 2026; Cash + cash equivalents + marketable securities: $964.8 million. Operating cash burn $352M annually. Rough runway:$965M / $352M ≈ 2.7 years - cash risk low. That is all that matters to me - that is my truth. Now - a little bit less than 2 months left for the PDUFA catalyst. Good time to buy AGIO. Personally I currently sell puts on AGIO with expiration before Nov 1st. The important piece for all biotechs not to carry stock via binary event but to sell it before, presumably no later than 2 weeks to lock the biorunup profit. That is all.
View on StockTwits ↗
$AGIO any truth !!! They lied about liver reaction until they sold their qtrly given options to sell. They lied more recently of the trial they ended. They knew in phase 1/b , CMO Sara G , sells stock like an addiction to drugs ,and she sees and creates the trials . Her experience is so pathetic, so not genius ! Bowden was the secret , Schenkien was the first liar ! Street punished him, and still do, because he brought in a crony from Celgene , Fouse . Maraganore never asked him ( Schenkien) over to his new entity, City Therapeutics, yet, sat on his board at AGIOS for years . Guess disgust was the reason. Others from ALNY are on the board . Tells the public , the brains of AGIOS aren’t what is at ALNY . Get enough ??? @eeyore1 , Mike !!
View on StockTwits ↗$AGIO can anyone there tell the truth They are all liars …colons of Trump
View on StockTwits ↗
Stocks to Watch Tomorrow, Sep 4, 2026: $TE — Closed Near $4.51, Pivoting From Solar Into AI Data Centers $ARTV — Trading Near $9.78, a 300%+ Analyst Target Gap $SHIP — A Dry Bulk Shipper Near $18, Up 24.8% in Two Weeks $AGIO — A Hematology Biotech With $52-55 Analyst Targets $SHLS — Solar EBOS Maker Near $7, Guidance Raised https://truthsandnews.com/markets/10-stocks-to-watch-tomorrow-sept-4-2026-small-cap-movers
View on StockTwits ↗
Agios Pharmaceuticals ($AGIO) Stock Hub 2026: Can the Mitapivat Launch Carry the November 1 Sickle Cell Decision? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/
View on StockTwits ↗$AGIO the CEO’s have been a parade of failures Fouse…she ruined Bunge …goof Goff , he was a mere middle man at Alexion and let go No super scientists here for 7 years . Snowden laid the golden goose egg for these hacks to suck down a salary on ! He went with his brain to another start up in Mass. @Bornjever …
View on StockTwits ↗
$AGIO Stu - put on your CPAP machine and shut up.
View on StockTwits ↗
$AGIO so I do know this company has a sickle cell therapy that is in pill form and for years I lost money in therapy that was infused into folks but was not very effective and supposedly this therapy works and has limited side effects . So what else am I missing ??
View on StockTwits ↗$PLTR I wonder if us shareholders should have Karp, give CEO instructions to losers like Peter Tak , and hong dong Choung , Steve Hoerter , Brian Goff $CADL $BIVI , $AGIO … He might just help their sorry a$$ out of being siht CEO’s and the laugh of wall st … They say they are all ex Big Pharma , big wigs, lol I doubt that so very much !
View on StockTwits ↗$AGIO as a BUM DEVELOPER TRUMP so did, believe he could take IRAN, and failed So too, Jackie Fouse sold or actually had a fire sale auction of your oncology to parlay it to blood cancers Both Buffons , Trump and Fouse ..failed dismally !!! Each looking to another bunch of losers , to fix it ,,, and guess what ???? … They too are clueless …. happy investing at the Loser Camp, LLC Sidney st, Cambridge, ma
View on StockTwits ↗$AGIO the WHITE WELFARE OFFICE for rejected Biotech Execs ….salaries and options ..no concrete value expected from the company ….Sign Up !! Fouse did , Goff was unemployed…the money makers left !!! Chris Bowden and his team
View on StockTwits ↗$AGIO There you have it THE CHIEF MEDICAL OFFICER TOUTS ONE THING And DOES THE COMPLETE OPPOSITE…a SELLER of HER DISCOVERIES , or of NOT HER DICOVERIES ..FRAUD Never , Ever a BUYER ….NOR IS GOOF BALL , GOFF , ceo
View on StockTwits ↗$AGIO Morgan ???? Every useless senior exec get their shares out, via you clowns today and your little run ??? They suck at their jobs, they need you every qtr !!!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.